Heisenberg models and a particular isotropic model

The Heisenberg model, a quantum mechanical analogue of the Ising model, has a large ground state degeneracy, due to the symmetry generated by the total spin. This symmetry is also responsible for degeneracies in the rest of the spectrum. We discuss the global structure of the spectrum of Heisenberg models with arbitrary couplings, using group theoretical methods. The Hilbert space breaks up in blocks characterized by the quantum numbers of the total spin, $S$ and $M$, and each block is shown to constitute the representation space of an explicitly given irreducible representation of the symmetric group $S_N$, consisting of permutations of the $N$ spins in the system. In the second part of the paper we consider, as a concrete application, the model where each spin is coupled to all the other spins with equal strength. Its partition function is written as a single integral, elucidating its $N$-dependence. This provides a useful framework for studying finite size effects. We give explicit results for the heat capacity, revealing interesting behavior just around the phase transition.Comment: 16 pages LaTeX, one of the 2 figures included as a postscript file. Oxford preprint OUTP-93-18S, to be published in Phys. Rev.

Modified iterative versus Laplacian Landau gauge in compact U(1) theory

Compact U(1) theory in 4 dimensions is used to compare the modified iterative and the Laplacian fixing to lattice Landau gauge in a controlled setting, since in the Coulomb phase the lattice theory must reproduce the perturbative prediction. It turns out that on either side of the phase transition clear differences show up and in the Coulomb phase the ability to remove double Dirac sheets proves vital on a small lattice.Comment: 14 pages, 8 figures containing 23 graphs, v2: 2 figures removed, 2 references adde

Sphaleron Transition Rate in Presence of Dynamical Fermions

We investigate the effect of dynamical fermions on the sphaleron transition rate at finite temperature for the Abelian Higgs model in one spatial dimension. The fermion degrees of freedom are included through bosonization. Using a numerical simulation, we find that massless fermions do not change the rate within the measurement accuracy. Surprisingly, the exponential dependence of the sphaleron energy on the Yukawa coupling is not borne out by the transition rate, which shows a very weak dependence on the fermion mass.Comment: 20 pages, 7 figures, LaTeX, psfi

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

In pursuing personalized medicine, pharmacogenomic (PGx) knowledge may help guide prescribing drugs based on a person’s genotype. Here we evaluate the feasibility of incorporating PGx knowledge, combined with clinical data, to support clinical decision-making by: 1) analyzing clinically relevant knowledge contained in PGx knowledge resources; 2) evaluating the feasibility of a rule-based framework to support formal representation of clinically relevant knowledge contained in PGx knowledge resources; and, 3) evaluating the ability of an electronic medical record/electronic health record (EMR/EHR) to provide computable forms of clinical data needed for PGx clinical decision support. Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement information contained in FDA approved drug labels. Furthermore, we found that with supporting knowledge (e.g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington’s EMR systems to support 50% of PGx knowledge contained in drug labels that could be expressed as rules

The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion

Background: Drug-disease interactions negatively affect the benefit/risk ratio of drugs for specific populations. In these conditions drugs should be avoided, adjusted, or accompanied by extra monitoring. The motivation for many drug-disease interactions in the Summary of Product Characteristics (SmPC) is sometimes insufficiently supported by (accessible) evidence. As a consequence the translation of SmPC to clinical practice may lead to non-specific recommendations. For the translation of this information to the real world, it is necessary to evaluate the available knowledge about drug-disease interactions, and to formulate specific recommendations for prescribers and pharmacists. The aim of this paper is to describe a standardized method how to develop practice recommendations for drug-disease interactions by literature review and expert opinion. Methods: The development of recommendations for drug-disease interactions will follow a six-step plan involving a multidisciplinary expert panel (1). The scope of the drug-disease interaction will be specified by defining the disease and by describing relevant effects of this drug-disease interaction. Drugs possibly involved in this drug-disease interaction are selected by checking the official product information, literature, and expert opinion (2). Evidence will be collected from the official product information, guidelines, handbooks, and primary literature (3). Study characteristics and outcomes will be evaluated and presented in standardized reports, including preliminary conclusions on the clinical relevance and practice recommendations (4). The multidisciplinary expert panel will discuss the reports and will either adopt or adjust the conclusions (5). Practice recommendations will be integrated in clinical decision support systems and published (6). The results of the evaluated drug-disease interactions will remain up-to-date by screening new risk information, periodic literature review, and (re)assessments initiated by health care providers. Actionable Recommendations: The practice recommendations will result in advices for specific DDSI. The content and considerations of these DDSIs will be published and implemented in all Clinical Decision Support Systems in the Netherlands. Discussion: The recommendations result in professional guidance in the context of individual patient care. The professional will be supported in the decision making in concerning pharmacotherapy for the treatment of a medical problem, and the clinical risks of the proposed medication in combination with specific diseases

Clinically relevant potential drug-drug interactions in intensive care patients:A large retrospective observational multicenter study

Purpose: Potential drug-drug interactions (pDDIs) may harm patients admitted to the Intensive Care Unit (ICU). Due to the patient's critical condition and continuous monitoring on the ICU, not all pDDIs are clinically relevant. Clinical decision support systems (CDSSs) warning for irrelevant pDDIs could result in alert fatigue and overlooking important signals. Therefore, our aim was to describe the frequency of clinically relevant pDDIs (crpDDIs) to enable tailoring of CDSSs to the ICU setting. Materials & methods: In this multicenter retrospective observational study, we used medication administration data to identify pDDIs in ICU admissions from 13 ICUs. Clinical relevance was based on a Delphi study in which intensivists and hospital pharmacists assessed the clinical relevance of pDDIs for the ICU setting. Results: The mean number of pDDIs per 1000 medication administrations was 70.1, dropping to 31.0 when considering only crpDDIs. Of 103,871 ICU patients, 38% was exposed to a crpDDI. The most frequently occurring crpDDIs involve QT-prolonging agents, digoxin, or NSAIDs. Conclusions: Considering clinical relevance of pDDIs in the ICU setting is important, as only half of the detected pDDIs were crpDDIs. Therefore, tailoring CDSSs to the ICU may reduce alert fatigue and improve medication safety in ICU patients

The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview

Aziz Sheikh and colleagues report the findings of their systematic overview that assessed the impact of eHealth solutions on the quality and safety of health care

Seeman. Maritiem woordenboek van Wigardus à Winschooten, met een cd-rom met diverse zeemanswoordenboeken

Item does not contain fulltex